Form 4: X4 Pharmaceuticals Director Gary Bridger Receives Annual Equity Award

X4 Pharmaceuticals, Inc. Director Gary Bridger was granted 1,500 restricted stock units as an annual award for his service on the Board of Directors.

Summary

• Gary Bridger, a Director of X4 Pharmaceuticals, Inc. (XFOR), acquired 1,500 shares of Common Stock on June 9, 2025.
• These shares represent restricted stock units (RSUs) granted as an annual award for his service on the Board of Directors.
• The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service.
• Full vesting will also occur upon a change in control of X4 Pharmaceuticals, Inc.
• Following this transaction, Gary Bridger beneficially owns a total of 4,722 shares of Common Stock.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While a routine compensation event, it signifies continued alignment of a director's interests with shareholders and adherence to standard corporate governance practices. It does not, however, indicate any extraordinary operational or financial performance.

Positives

• The grant of restricted stock units to a director aligns their interests with those of shareholders, incentivizing long-term company performance.
• This is a standard practice for compensating board members, indicating adherence to common corporate governance structures.

Negatives

• No specific negative aspects are identified within this routine insider transaction report.

Risks

• The value of the granted restricted stock units is subject to the future performance and market price of X4 Pharmaceuticals' common stock.
• The RSUs are subject to forfeiture if the reporting person's board service ceases prior to the applicable vesting date, unless a change in control occurs.

Future Outlook

The restricted stock units are set to vest on the earlier of the one-year anniversary of the grant date or the Issuer's next annual meeting of stockholders, contingent on continued board service. Full vesting will also occur upon a change in control of the Issuer.

Industry Context

The granting of restricted stock units to directors is a common and widely accepted practice across publicly traded companies, particularly in the biotechnology and pharmaceutical sectors, as a means of non-cash compensation that aligns the interests of board members with those of shareholders.

Comparison to Industry Standards

• The practice of granting restricted stock units (RSUs) as part of director compensation is a standard industry practice, widely adopted by companies across various sectors, including biotechnology and pharmaceuticals.
• This method of compensation is comparable to practices seen in companies like Biogen Inc. or Moderna, Inc., where equity awards are used to incentivize long-term commitment and performance from board members.
• The vesting schedule, tied to continued service and accelerated by a change in control, is also typical for such equity grants in the industry.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with those of the shareholders, potentially leading to more shareholder-centric decision-making.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• The restricted stock units will vest according to the specified schedule (earlier of one-year anniversary or next annual meeting, or upon change in control), subject to continued board service.

Key Dates

Recommendation

Keywords

X4 Pharmaceuticals, XFOR, Form 4, SEC filing, Restricted Stock Units, RSU, Director compensation, equity award, insider transaction, corporate governance